US Patent

US10370406 — Salts and polymorphs of SCY-078

Method of Use · Assigned to Scynexis Inc · Expires 2035-01-19 · 9y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects novel salts and polymorph forms of SCY-078, a glucan synthase inhibitor with antimicrobial activity.

USPTO Abstract

SCY-078 is a glucan synthase inhibitor with antimicrobial activity. Novel salts and polymorph forms of SCY-078 are disclosed herein. The disclosure also relates to pharmaceutical compositions, methods of use, and methods of preparing the novel salts and polymorphs of SCY-078.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3159 — Brexafemme

Patent Metadata

Patent number
US10370406
Jurisdiction
US
Classification
Method of Use
Expires
2035-01-19
Drug substance claim
No
Drug product claim
No
Assignee
Scynexis Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.